Daniel A. Ninivaggi - 13 May 2026 Form 4 Insider Report for Indivior Pharmaceuticals, Inc. (INDV)

Reporting relationship: Director
Issuer ticker: INDV
Reported as of: 13 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 May 2026, 16:10:01 UTC
Prior SEC filing: 02 Apr 2026
Next SEC filing: 15 May 2026
Source filing: View source filing
Reporting owner signature: /s/Alice Givens, Power of Attorney

Key filing fact

Daniel A. Ninivaggi filed Form 4 for Indivior Pharmaceuticals, Inc. (INDV) on 14 May 2026.

Key facts

This page summarizes Daniel A. Ninivaggi's Form 4 filing for Indivior Pharmaceuticals, Inc. (INDV).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 14 May 2026, 16:10.

Change

Previous filing in this sequence was filed on 02 Apr 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001257599 Primary reporting owner

NINIVAGGI DANIEL A

Relationship: Director
Address: 10710 MIDLOTHIAN TURNPIKE, SUITE 125, NORTH CHESTERFIELD
Signature: /s/Alice Givens, Power of Attorney
Signature date: 14 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

INDV transaction

Common Stock

Award

Transaction value
Shares: +6,518
Change %: +32%
Price: $0.000000^*
Shares after: 27,163
Date: 13 May 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Reflects a grant of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the day immediately preceding the date of the annual meeting of the Issuer's stockholders following the date of grant, subject to the Reporting Person's continued service to the Issuer on the vesting date.